RS50091B - Upotreba retigabina u lečenju neuropatskog bola - Google Patents

Upotreba retigabina u lečenju neuropatskog bola

Info

Publication number
RS50091B
RS50091B YUP-203/02A YUP20302A RS50091B RS 50091 B RS50091 B RS 50091B YU P20302 A YUP20302 A YU P20302A RS 50091 B RS50091 B RS 50091B
Authority
RS
Serbia
Prior art keywords
treatment
neuropathic pain
retigabine
prophylaxis
manufacture
Prior art date
Application number
YUP-203/02A
Other languages
English (en)
Inventor
Chris Rundfeldt
Angelika Rostock
Christine Tober
Rita Dost
Reni Bartsch
Original Assignee
Viatris Gmbh. & Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh. & Co.Kg., filed Critical Viatris Gmbh. & Co.Kg.,
Publication of YU20302A publication Critical patent/YU20302A/sh
Publication of RS50091B publication Critical patent/RS50091B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Upotreba jedinjenja I ili njegovih farmaceutski upotrebljivih soli, za proizvodnju farmaceutskih proizvoda za profilaksu i lečenje neuropatskog bola. Prijava sadrži još 5 patentnih zahteva.
YUP-203/02A 1999-09-27 2000-09-22 Upotreba retigabina u lečenju neuropatskog bola RS50091B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain

Publications (2)

Publication Number Publication Date
YU20302A YU20302A (sh) 2005-03-15
RS50091B true RS50091B (sr) 2009-01-22

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-203/02A RS50091B (sr) 1999-09-27 2000-09-22 Upotreba retigabina u lečenju neuropatskog bola

Country Status (35)

Country Link
US (1) US6117900A (sr)
EP (1) EP1223927B1 (sr)
JP (1) JP2003510273A (sr)
KR (1) KR100730829B1 (sr)
CN (2) CN100522155C (sr)
AR (1) AR026163A1 (sr)
AT (1) ATE288748T1 (sr)
AU (1) AU777764B2 (sr)
BG (1) BG65795B1 (sr)
BR (1) BR0014293A (sr)
CA (2) CA2384504C (sr)
CZ (1) CZ295980B6 (sr)
DE (1) DE50009504D1 (sr)
DK (1) DK1223927T3 (sr)
EE (1) EE05073B1 (sr)
ES (1) ES2237461T3 (sr)
HK (1) HK1052471A1 (sr)
HR (1) HRP20020234A2 (sr)
HU (1) HUP0202853A3 (sr)
IL (3) IL148309A0 (sr)
IS (1) IS6303A (sr)
MX (1) MXPA02003179A (sr)
NO (1) NO329744B1 (sr)
NZ (1) NZ517616A (sr)
PL (1) PL200847B1 (sr)
PT (1) PT1223927E (sr)
RS (1) RS50091B (sr)
RU (1) RU2264813C2 (sr)
SI (1) SI1223927T1 (sr)
SK (1) SK286057B6 (sr)
TR (1) TR200200706T2 (sr)
TW (1) TWI257304B (sr)
UA (1) UA72550C2 (sr)
WO (1) WO2001022953A2 (sr)
ZA (1) ZA200202449B (sr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525062B2 (en) * 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US20040122008A1 (en) * 2002-09-05 2004-06-24 Protter Andrew A. Treatment of pain by inhibition of p38 MAP kinase
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
SI1578740T1 (sl) * 2002-12-27 2007-08-31 Lundbeck & Co As H Derivati 1,2,4-triaminobenzena, uporabni pri zdravljenju motenj osrednjega ĺ˝iväśnega sistema
MXPA05006463A (es) * 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
MX2007010547A (es) 2005-03-03 2007-10-03 Lundbeck & Co As H Derivados de piridina sustituidos.
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
CA2661462C (en) * 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (de) * 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
MX2011000636A (es) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Formulacion de liberacion modificada y metodos de uso.
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
US11369593B2 (en) 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
ES2237461T3 (es) 2005-08-01
CA2384504C (en) 2009-05-26
RU2264813C2 (ru) 2005-11-27
RU2002109240A (ru) 2004-01-10
EE200200145A (et) 2003-04-15
SK286057B6 (sk) 2008-02-05
WO2001022953A2 (de) 2001-04-05
SK2922002A3 (en) 2002-08-06
KR100730829B1 (ko) 2007-06-20
SI1223927T1 (sr) 2005-08-31
ATE288748T1 (de) 2005-02-15
BR0014293A (pt) 2002-05-21
BG65795B1 (bg) 2009-12-31
CZ295980B6 (cs) 2005-12-14
IS6303A (is) 2002-03-18
CA2659048A1 (en) 2001-04-05
AR026163A1 (es) 2003-01-29
CN101444498A (zh) 2009-06-03
HUP0202853A3 (en) 2003-10-28
DE50009504D1 (de) 2005-03-17
NO20021418L (no) 2002-03-21
YU20302A (sh) 2005-03-15
PT1223927E (pt) 2005-06-30
AU777764B2 (en) 2004-10-28
JP2003510273A (ja) 2003-03-18
US6117900A (en) 2000-09-12
HRP20020234A2 (en) 2003-06-30
NZ517616A (en) 2002-12-20
EP1223927A2 (de) 2002-07-24
NO329744B1 (no) 2010-12-13
MXPA02003179A (es) 2003-08-20
EE05073B1 (et) 2008-10-15
HK1052471A1 (zh) 2003-09-19
CN1409632A (zh) 2003-04-09
IL187030A (en) 2011-06-30
ZA200202449B (en) 2003-03-26
CA2384504A1 (en) 2001-04-05
PL200847B1 (pl) 2009-02-27
IL148309A (en) 2007-12-03
PL353393A1 (en) 2003-11-17
TWI257304B (en) 2006-07-01
TR200200706T2 (tr) 2002-10-21
WO2001022953A3 (de) 2002-05-23
IL187030A0 (en) 2008-02-09
KR20020042691A (ko) 2002-06-05
UA72550C2 (en) 2005-03-15
AU7906100A (en) 2001-04-30
BG106450A (en) 2002-09-30
NO20021418D0 (no) 2002-03-21
IL148309A0 (en) 2002-09-12
EP1223927B1 (de) 2005-02-09
HUP0202853A2 (hu) 2002-12-28
CZ2002989A3 (cs) 2002-08-14
CN100522155C (zh) 2009-08-05
DK1223927T3 (da) 2005-04-11

Similar Documents

Publication Publication Date Title
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
SE0102315D0 (sv) Compounds
ATE231872T1 (de) Thiazolopyrimidinderivate
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
DE69907977D1 (de) Pyrrolobenzodiazepine
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
SE0100901D0 (sv) New composition
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
RS49795B (sr) Sredstva sa antidepresivnim dejstvom
SE9802208D0 (sv) Novel compounds
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
BG105256A (en) Muscarinic agonists and antagonists
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
SE9802209D0 (sv) Novel compounds
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
NO20005548L (no) Mykobakterieinhibitorer
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent